Multidisciplinary management of very advanced stage III and IV melanoma: Proof-of-principle

HAIM GUTMAN¹, EYTAN BEN-AMI², RONI SHAPIRA-FROMMER² and JACOB SCHACHTER²

¹Department of Surgery, Rabin Medical Center, Beilinson Campus;
²Ella Institute for Treatment and Research of Melanoma, Ch Sheba Medical Center, Tel Aviv University, Sackler School of Medicine, Israel

Abstract. Patients with potentially resectable advanced stage III and IV melanoma are a selected subgroup that gain maximal advantage if treated in a melanoma center. Surgery combined with chemo/chemobiotherapy may yield durable remission and long-term palliation. Thirty-seven non-randomly selected patients underwent systemic therapy with the aim of consolidating treatment by surgery. Data were collected prospectively, and analyzed retrospectively. The median follow-up from diagnosis was 50 (3-307) months and 15 (1-156) months when calculated from the last intervention. Twenty-two males and 15 females, with a median age at diagnosis of 44 (20-71) years, with 13 trunk, 13 extremity, 3 head and neck and 8 unknown primary melanomas were included. There were 17 stage III and 20 stage IV patients with a median Breslow thickness of 3.7 (0.45-26) mm. Chemo/chemobiotherapy achieved 7 clinical complete responses (cCRs), 28 partial responses (PRs) and 2 instances of stable disease. Six of the 7 cCRs were operated on, securing pathological complete response (NED) in 5 and PR in one. Four of these five and the PR patient still have no evidence of disease (NED). Twenty-one of 30 PR patients were rendered NED by surgery; 14 of these 21 patients succumbed to melanoma, and one is alive with stable disease. Overall, 11 of 37 patients have not succumbed to melanoma, with a median of 72 (14-156) months survival following the last intervention. Of the eight patients with unknown primary melanomas, five have not succumbed to melanoma, with a median of 89 (30-156) months survival following the last intervention. Patients with marginally resectable stage III and IV melanoma have a significant 30% chance, according to this series, for durable remission if treated by a multidisciplinary team in a melanoma center using induction chemobiotherapy and surgery. Results are more favorable for patients with an unknown primary lesion. In view of the currently approved new effective treatments for melanoma, this study may be considered a proof-of-principle investigation, enabling long-term remissions by combining induction therapy and surgery.

Introduction

Based on the 2006 Surveillance Epidemiology and End Results (SEER) database, the incidence of melanoma is 19.6 per 100,000 population per year in the US, with mortality rates at 2.7 per 100,000 (1). Rates in Israel are not significantly different with 1,200 new cases being reported per year per 7,000,000 population. The favorable incidence to mortality ratio reflects the fact that most melanoma patients are diagnosed at an early, surgically curable stage. Approximately 8,400 patients per year in the US either presented with or developed incurable disease, and succumbed to melanoma (1).

Although surgery provides the best opportunity for cure, it is frequently futile or impossible in patients with advanced stage III or IV metastatic disease. Thus, a multidisciplinary approach is an option that should be applied to this subgroup of patients, in an attempt at improving their outcome.

In their 1998 phase II chemobiotherapy (CBT) study, Buzaid et al achieved 6.5% pathological complete response (pCR) and 43.5% partial response (PR) in 65 potentially resectable stage III melanoma patients (2). Stein et al used CBT to achieve 17% CR in 29 stage IV patients with 8 months median time to progression (3). Gibbs et al reported clinical complete response (cCR) in 2.8% of 48 stage III patients, pCR in 11.1% and 36% PR, using combined preoperative and postoperative CBT, with 64.6% of patients being disease-free following a median follow-up of 31 months (4). Researchers from Yale University identified 16 patients who responded to combination chemotherapy and had their residual tumor resected. Eleven of these 16 were alive with no evidence of disease (NED) following a median of 35 months (5).

Our own experience with CBT echoes the results of these publications with a 44% (28 of 57 patients) response rate, 25% (14 patients) CR and 19% (11 patients) PR (6).

Based on these observations, and specifically, the high response rate, the CBT regimen was considered and applied.
as the treatment of choice to precede or be combined with surgery for selected patients who were deemed potentially resectable or became potentially resectable during treatment.

Patients and methods

Patient selection. The Institutional Melanoma Tumor Boards selected 37 cutaneous melanoma patients diagnosed between January 1983 and October 2006 in a non-randomized manner. These patients presented with or developed very advanced stage III or IV disease, and were deemed eligible for induction CBT followed by potentially curative surgery (Table I).

Very advanced stage III was defined as irresectable or marginally resectable regional disease, based on surgical oncologist’s clinical examination, computed tomography (CT) or positron emission tomography-computed tomography (PET-CT) plus magnetic resonance imaging (MRI) of brain and multidisciplinary team deliberation. Stage IV for inclusion in this study required biopsy-proven distant metastases combined with progression on imaging.

The study was approved by the ethics committee of the hospital. Signed informed consent was obtained from the patient prior to commencing chemotherapy treatment.

Methods. Patients had to be on no active treatment for at least two weeks prior to the initiation of CBT. All 37 patients had an ECOG performance status of 0-2; white blood cell count>3000; platelet count >100,000; normal renal function tests; bilirubin <2 mg%; and normal thyroid function tests. Symptomatic patients or those aged >50 underwent a Thallium 201 Effort Stress Cardiac Perfusion Test and/or lung function test (>75% of predicted). Systemic evaluation included head, chest and abdominal CT or PET-CT with MRI of brain. Patients on corticosteroids, with other malignancies or brain metastases or known mucosal primary malignancies were excluded.

Two chemotherapy regimens were used (Table II), both using interferon-α (Intron A®; Schering, Kenilworth, NJ, USA), dacarbazine and cisplatin. BCNU and granulocyte-monocyte colony stimulating factor (GMCSF), which were both the first regimens were replaced by decrescendo interleukin 2 (IL-2) (Proleukin®; Hoffman La Roche, Nutley, NJ, USA) due to the questionable contribution of BCNU and its significant side-effects, the unavailability of GMCSF in Israel, and the activity of IL-2 in metastatic melanoma.

Response evaluation was performed at the end of every two courses combining clinical examination, CT or PET-CT comparative study and multidisciplinary team evaluation. Surgical intervention was considered at each interval. CBT was stopped if progressive disease was noted.

Results

Thirty-seven patients were included in this analysis (Table I, Fig. 1), of whom 4 did not undergo surgery. Of these 4 patients, 2 patients never became resectable, and succumbed to their disease. One patient achieved temporary CR (PET-CT), but had a recurrence prior to consenting to undergo surgery. The fourth patient is alive with NED 108 months following emergency surgical removal of large metastatic bleeding ulcerating axillary disease of unknown primary malignancy and the disappearance of biopsy proven liver and prostate metastases. Thirty-four patients underwent surgery following a median of 4 CBT courses, and 27 achieved CR. Patients who did not have surgery (N=3), and those in whom surgery failed to remove all residual disease (N=7), succumbed to melanoma. Similarly, 16 patients who were rendered disease-free by CBT and surgery combined succumbed to the disease.

Of the 37 patients, 11 patients (30%) did not succumb to melanoma during the median follow-up period of 72 (14-156) months following the last intervention. One of these 11 patients succumbed to non-small-cell lung cancer 87 months following the last intervention for melanoma. Another patient was alive with diminishing disease and expanding vitiligo 25 months from the last intervention, at the time of data analysis. The patient remains alive with no active disease over 30 months later.

Five of 8 patients with unknown primary survived with NED for a median of 89 (30-156) months since the last intervention.

Discussion

CBT regimens have been employed to treat melanoma patients. Although high response rates were documented (2-4,6), phase III studies failed to show survival advantage to CBT over the standard single agent DTIC, and were associated with significant toxicity (7). Furthermore, the exact role of each component of these multi-agent regimens has not been well defined. Thus, these regimens have not matured into a standard first-line treatment. A number of clinical studies are ongoing to find the best regimen. By applying modern targeted
Two of these new studies yielded two new highly effective, life-prolonging, drugs in metastatic melanoma. The high response rates of CBT regimens have also been the focus of other studies. Hwu et al rendered 3 of 35 stage IV patients NED by surgery following temozolomide and interferon induction treatment (8). In their study, Lewis et al reported a 26% response rate using preoperative and postoperative CBT (9). Even peri-operative interferon alone was able to achieve up to 55% PR with 15% pCR (10). However, a more recent combination containing cisplatin, paclitaxel and sorafenib failed to induce a response rate of this magnitude (11).

The traditional CBT regimens created the best opportunity for a significant response during the study period (7). Thus, it seemed reasonable to regard these patients as resectable and attempt surgery to render the responders NED in order to secure long-term remission. The role of surgery is not well defined in those patients rendered cCR by the induction therapy alone. The mere presence of microscopic residual disease places the patients at a potential risk of recurrence, thus, surgery appears crucial to secure CR and long-term remission. The present study may serve as a proof-of-principle, since 30% long term remission achieved is not perceived as typical natural history of advanced stage III and IV melanoma.

The use of a priori CBT is significant for various reasons. Quality of life indices are better in responders compared to supportive care, and responders are more likely to benefit from further treatments (12), as demonstrated in the present

Table II. Chemohiotherapy (CBT) regimens.

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Dose</th>
<th>Initiation point</th>
</tr>
</thead>
<tbody>
<tr>
<td>INF α (s.c.)</td>
<td>3 mU/days 1,3,5</td>
<td>Week I</td>
</tr>
<tr>
<td>DTIC (i.v.)</td>
<td>220 mg/m²/days 1-3</td>
<td>Week II</td>
</tr>
<tr>
<td>CDDP (i.v.)</td>
<td>25 mg/m²/days 1-3</td>
<td>Week II</td>
</tr>
<tr>
<td>BCNU (i.v.)</td>
<td>150 mg/m²/day 1</td>
<td>Week II</td>
</tr>
<tr>
<td></td>
<td>(every 2nd course)</td>
<td></td>
</tr>
<tr>
<td>GMCSF (s.c.)</td>
<td>20 µg/m²/days 1-7</td>
<td>Week III</td>
</tr>
</tbody>
</table>

A. Earlier regimen (N=13), Q-21 day (16).

B. Later regimen (N=24), Q-21 day.

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>INF α (s.c.)</td>
<td>5 mU/days 1-21</td>
</tr>
<tr>
<td>DTIC (i.v.)</td>
<td>220 mg/m²/days 1-3</td>
</tr>
<tr>
<td>CDDP (i.v.)</td>
<td>25 mg/m²/days 1-3</td>
</tr>
<tr>
<td>IL-2 (i.v.)</td>
<td>18 mU/m²/day 1</td>
</tr>
<tr>
<td></td>
<td>9 mU/m²/day 2</td>
</tr>
<tr>
<td></td>
<td>4.5 mU/m²/day 3-4</td>
</tr>
</tbody>
</table>

s.c., subcutaneous; i.v., intravenous; INF, interferon α 2b; DTIC, dacarbazine; CDDP, cisplatin; IL-2, interleukin 2; GMCSF, granulocyte-monocyte colony stimulating factor.
series. Surgery for responders may be of a lesser extent and less mutilating. Surgery may be omitted for non-responders. Hypothetically, the induction therapy also ‘sterilizes’ the periphery of the tumor mass, thus reducing the surgical field and intravascular tumor cell shedding (13). Although direct evidence to support this hypothesis is scarce, the overall results of this study may be, in part, due to such an effect. Response to CBT facilitates and encourages surgical attempts. Disease progression is an indicator that CBT treatment is more beneficial than surgery. Surgery for responders results in clinically meaningful prolongation of remission in an, admittedly low, but significant percentage of these advanced stage patients.

Numerous studies in favor of surgical resection of metastatic melanoma in selected populations have been published and reviewed (14,15). Adding induction CBT may improve patient selection for surgery, reduce its extent, and improve quality of life. Patients with reasonable performance status, whose metastatic disease may become resectable, should be offered the option of this multidisciplinary approach, which is currently the only one with up to 30% chance of an unmaintained remission.

Recently, extensive clinical experience has been gained with the use of new technologies for advanced melanoma such as B-RAF inhibitors and anti CTLA-4 antibodies. The group of the B-RAF inhibitors has shown a notable, albeit short clinical response of more than 50% and is potentially applicable to the above neoadjuvant multidisciplinary approach (Chapman et al, American Society of Clinical Oncology 2011 meeting, abs. LBA4, 2011).

References